Cargando…

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy

Purpose: Immune checkpoint inhibitors (ICIs) have been successfully used in many clinical trials related to immunotherapy. This study aimed to investigate the clinical efficacy of ICIs and prognostic factors in patients with resectable non-small cell lung cancer (NSCLC) following neoadjuvant therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zuo, Gao, Zhaoming, Zhang, Mengzhe, Wang, Xiaofei, Gong, Jialin, Jiang, Shuai, Zhang, Zhenfa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081467/ https://www.ncbi.nlm.nih.gov/pubmed/34776459 http://dx.doi.org/10.5761/atcs.oa.21-00143

Ejemplares similares

Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
por: Deboever, Nathaniel, et al.
Publicado: (2022)

A predictive nomogram for lymph node metastasis in part-solid invasive lung adenocarcinoma: A complement to the IASLC novel grading system
por: Gao, Zhaoming, et al.
Publicado: (2022)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside
por: Wang, Xiaofei, et al.
Publicado: (2021)

Neoadjuvant immunotherapy combined with chemotherapy in the treatment of stage III lung squamous cell carcinoma: a retrospective cohort study
por: Guo, Jing, et al.
Publicado: (2023)

IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
por: Fukuda, Keitaro
Publicado: (2023)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
Publicado: (2023)

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)

Risk factors and survival analysis of arrhythmia following lung cancer surgery: a retrospective study
por: Gong, Jialin, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy
por: Groenewold, M.D., et al.
Publicado: (2022)

Quality of life after lung cancer surgery: sublobar resection versus lobectomy
por: Jiang, Shuai, et al.
Publicado: (2023)

Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2009)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy
por: TAKAHASHI, RYUJI, et al.
Publicado: (2013)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)
por: Faehling, Martin, et al.
Publicado: (2022)

A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence
por: He, Tao, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
por: Zaher, Haidi Abd El, et al.
Publicado: (2023)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer
por: Zhu, Jun, et al.
Publicado: (2017)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
por: Brun, Jean-Luc, et al.
Publicado: (2009)

Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
por: Tang, Rong, et al.
Publicado: (2023)

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects
por: Zhao, Xiaoliang, et al.
Publicado: (2016)

Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy
por: Jin, Hailong, et al.
Publicado: (2013)

Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?
por: Luu, Carrie, et al.
Publicado: (2017)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fg9tk0lh2touapj5u1autrdenf